Applications of Pemirolast in Industrial Manufacturing

Pemirolast, a pyrimidone-based compound widely used for its mast cell stabilizing properties, is produced at industrial scale for specific sectors requiring high-purity actives and excipients. The following sections detail established application scenarios where pemirolast serves as a critical raw material, with a focus on compliance, process positioning, and product integration for B2B buyers.

1. Ophthalmic Pharmaceutical Preparations

Ophthalmic drug manufacturers use pemirolast as an active pharmaceutical ingredient in anti-allergic eye drop formulations targeting allergic conjunctivitis. Bulk pemirolast integrates during the aqueous solution stage, demanding strict control in aseptic environments. Production lines emphasize high-purity input to meet regulatory thresholds for API content, particulate matter, and sterility throughout lot preparation and final packaging, ensuring compliance for international supply.

Industry compliance standards

• Pharmacopoeia: USP, EP, JP – active ingredient monographs
• ICH Q7 GMP for APIs
• FDA CFR 21 Part 211 (Finished Pharmaceuticals)
• ISO 13485 for medical devices (primary packing materials)

Typical usage ratio

• 0.1% to 0.2% w/v in sterile aqueous solution, adjusted based on target region regulatory maximum concentration and compatibility with buffering agents

Downstream process integration

• Melt or dissolve in deionized water during solution compounding, followed by pH adjustment, filtration (0.22 μm), and aseptic filling

Final product types

• Single-dose unit and multi-dose bottle ophthalmic solutions formulated for allergic conjunctivitis treatment

2. Anti-Allergic Nasal Spray Formulations

The pharmaceutical sector employs pemirolast in combination or monotherapy nasal sprays for patients suffering from allergic rhinitis. Ingredient purity, solubility, and low metallic ion content ensure reliable performance during microdosing. During production, the raw material is dissolved and filtered before being filled into pressurized or pump nasal applicators, with precise controls preventing aggregation or crystallization in storage.

Industry compliance standards

• Pharmacopoeia: USP, JP, or customer country-specific standards
• GMP for Non-Sterile Pharmaceutical Products
• Good Distribution Practice (GDP) for transportation of pharmaceutical-grade APIs
• ISO 9001:2015 certified quality management systems for raw ingredient supply

Typical usage ratio

• 0.2% to 0.3% w/v; exact formulation determined by maximum daily dose requirements outlined by local drug authorities, nasal mucosal tolerance testing, and product stability evaluation

Downstream process integration

• Dissolve into buffered saline base during aqueous phase blending, sterile filtration, and subsequent filling into nasal spray primary containers; compatibility tested alongside preservatives and excipients

Final product types

• Metered-dose nasal sprays for allergic and non-infective rhinitis symptom management

3. Oral Solid Dosage Antihistamine Blends

Global drug formulating firms deploy pemirolast as part of multi-component tablets or capsules targeting chronic allergy symptoms. Blending as a micronized powder, it requires batchwise content uniformity checks, particularly when combined with other actives or controlled-release excipients. Wet granulation or direct compression techniques depend upon excipient compatibility and dissolution profile requirements for each jurisdiction.

Industry compliance standards

• Applicable pharmacopoeial monographs in USP, EP, JP
• PIC/s GMP for solid oral dose manufacturing
• 21 CFR Part 211 for recordkeeping, stability, and batch traceability
• Local or regional drug approval dossiers (e.g., FDA NDA/ANDA)

Typical usage ratio

• 5 mg to 20 mg per unit tablet or capsule, variable with patient age and therapy protocol; blend uniformity calculations verified by analytical batch testing

Downstream process integration

• Dry-blended with diluents, disintegrants, lubricants, and other APIs prior to granulation (for coated tablets), or direct-extruded into capsules

Final product types

• Allergy relief tablets and hard-shell capsules for prescription and OTC use in chronic allergic conditions

4. Ingredient for Veterinary Anti-Allergy Preparations

Veterinary pharmaceutical producers formulate pemirolast into oral suspensions or tablets for companion animal allergy management, addressing atopic dermatitis and related immune-mediated responses. Suppliers must provide full impurity profile documentation, since animal health laws require absence of certain contaminants and confirmation of compliance with species-specific dosage guidelines. Dosage forms vary, so formulation teams adjust loading and process steps according to breed- and species-specific studies on bioavailability and palatability.

Industry compliance standards

• VICH GL9 Good Manufacturing Practice
• Pharmacopoeia: Veterinary monographs where available
• Animal Medicinal Drug Use Clarification Act (AMDUCA) compliance (US market)
• Veterinary Drugs Administration Ordinances (EU, China, Japan)

Typical usage ratio

• 1 mg/kg to 3 mg/kg body weight per day, dosage concentrated based on species, formulation type, and clinical protocol requirements

Downstream process integration

• Incorporate during final suspension blending for oral liquid formulations, or as part of powder blend for direct tablet compression; blending cycles controlled for homogeneous dispersion

Final product types

• Veterinary chewable tablets and oral suspensions for canine and feline anti-allergy applications